A NGFR-enriched CD44v6 CAR-T cell product coexpressing the TK suicide gene for switching-off potential toxicities (20, 31) will soon be investigated in a phase I/IIa clinical trial in relapsed/refractory AML and MM (EC-funded H2020 EURE-CART Consortium). This evidence concerns the gene NGFR and Miyoshi myopathy.